MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study.

What Was Tested

The paper reports a study of MOTS-c, published as a human research study.

Oxidative stress (OS) and endothelial dysfunction are major drivers of cardiovascular disease (CVD) in peritoneal dialysis (PD).

MOTS-c, a mitochondria-derived peptide, is emerging as a key regulator of skeletal muscle health, metabolic homeostasis, and vascular function, yet its role in the uremic environment remains unexplored.

The researchers investigated the relationship between MOTS-c levels, OS markers, and vascular stiffness in PD patients.

Who Took Part

The study group was 32 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger MOTS-c study would be practical.

MOTS-c levels were quantified in serum (sMOTS-c), urine (uMOTS-c), and peritoneal dialysate (dMOTS-c).

Systemic oxidative status was assessed via plasma Advanced Oxidation Protein Products (AOPPs).

Vascular function was evaluated by carotid-femoral Pulse Wave Velocity (PWV), and left ventricular systolic function was assessed echocardiographically.

What Was Measured

The subject headings attached to it are Oxidative Stress, Pilot Projects, Vascular Stiffness, Peritoneal Dialysis, Mitochondrial Proteins, Biomarkers and Pulse Wave Analysis.

The authors tagged it with the keywords AOPPs, MOTS-c and Pulse wave velocity.

What This Means in Plain Language

The paper is a pilot study of MOTS-c in 32 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (International urology and nephrology), a journal based in Netherlands.

More context: the MOTS-c compound page, all human trials.